Rapamycin for Longevity: What the PEARL Trial Showed
The PEARL trial was the first placebo-controlled RCT of low-dose rapamycin in healthy aging adults. Here is what it measured and what to track.
Rapamycin for Longevity: What the PEARL Trial Actually Showed **Rapamycin is the most replicated lifespan-extending compound in animal studies, but whether it slows human aging is still unproven as of 2026. The PEARL trial, short for Participatory Evaluation of Aging with Rapamycin for Longevity, was published in the journal Aging in 2025 and was the first placebo-controlled randomized trial of intermittent low-dose rapamycin in normal-aging healthy adults. It randomized 114 adults aged 50 to 85 to weekly 5 mg or 10 mg compounded rapamycin or placebo over 48 weeks, and adverse-event rates were similar to placebo. The most notable signal appeared in women on the 10 mg weekly dose, who gained about 6% lean tissue mass from baseline and reported less pain. PEARL measured body composition, pain, and safety over 48 weeks. It did not measure lifespan, and a 2025 George Washington University evidence review concluded that a human anti-aging benefit remains unproven.** Rapamycin sits at the center of the longevity conversation because of a strong and consistent animal record paired with a thin human one. This article walks through what the PEARL trial was designed to measure, what it found, what it deliberately did not test, and how a person following this space can organize their own data over time. The goal is to help you understand the evidence and track relevant markers, not to tell you what to take or how to take it. Rapamycin is a prescription medication, and any use for aging or healthspan is off-label and belongs in a conversation with your prescriber.
What Rapamycin Is, and Why It Is Not FDA-Approved for Aging
Rapamycin, also known by the generic name sirolimus, is an mTOR inhibitor. The mTOR pathway, short for mechanistic target of rapamycin, is a central nutrient-sensing system that tells cells when to grow and divide versus when to conserve and recycle. Slowing mTOR signaling in animals shifts cells toward maintenance and autophagy, and in multiple species this has extended lifespan.
Rapamycin is FDA-approved as an immunosuppressant to help prevent organ transplant rejection and for certain other specific indications. It is not FDA-approved for aging, longevity, or healthspan. Using it for those purposes is off-label, which means a licensed prescriber is making an individualized clinical judgment outside the labeled use. That distinction matters for interpreting any longevity study: the drug itself is well characterized, but the anti-aging application is investigational and, in humans, largely unproven.
Because rapamycin is a prescription immunosuppressant, this article gives no dosing protocol and no sourcing guidance. Those are clinician-directed decisions. What follows is a plain-language read of the published evidence and a framework for tracking your own health data.
What the PEARL Trial Was Designed to Measure
PEARL was structured as a placebo-controlled randomized controlled trial, the design that carries the most weight for causal questions. The trial randomized 114 adults aged 50 to 85 into three groups: weekly 5 mg compounded rapamycin, weekly 10 mg compounded rapamycin, or placebo. Participants were followed over 48 weeks. The medRxiv preprint of the trial was posted on August 21, 2024, and the peer-reviewed version appeared in the journal Aging in 2025.
Two features are worth underlining. First, the dosing was intermittent and low, once weekly rather than daily, which is the schedule many longevity-minded clinicians and researchers have gravitated toward to reduce side-effect burden. Second, the participants were normal-aging healthy adults, not patients being treated for a disease. That makes PEARL one of the first attempts to ask the healthspan question directly in people who are simply getting older.
The trial tracked a set of outcomes that included body composition, self-reported pain, quality-of-life measures, and safety and tolerability. It did not track lifespan, and it could not, given a 48-week window in middle-aged and older adults. Keep that scope in mind as you read the results.
The Headline Results
The clearest signal in PEARL came from women on the higher weekly dose. Women taking 10 mg of rapamycin weekly gained about 6% lean tissue mass from baseline and reported less pain over the trial period. Lean tissue mass, which reflects muscle and other non-fat tissue, tends to decline with age, so a measurable gain is a result researchers found notable.
On the safety side, adverse-event rates were similar to placebo across the trial. In plain terms, at these intermittent low doses over 48 weeks, the trial did not surface a safety signal that separated rapamycin from placebo. That is a meaningful tolerability finding for a drug whose reputation is shaped by its use at higher, continuous immunosuppressive doses in transplant medicine.
The table below summarizes the trial at a glance. Every figure in it is drawn directly from the published trial.
|---|---|
A single 48-week trial in 114 people is a starting point, not a verdict. The lean-mass and pain findings are promising and worth watching, but they emerged in a subgroup, women on the higher dose, which is exactly the kind of result that needs replication in larger trials before it can be treated as settled.
Why Rapamycin Gets So Much Attention
The reason rapamycin draws more longevity interest than almost any other molecule is its animal track record. It is the most replicated lifespan-extending compound in mammals, meaning independent labs, in multiple studies, have repeatedly shown it extends how long treated animals live. That kind of reproducibility is rare, and it is the foundation of the human interest.
But animal lifespan extension and human healthspan benefit are different claims separated by a large evidence gap. Mice are not small people, dosing schedules differ, and lifespan endpoints that take months in a mouse take decades in a human. This is precisely why a 2025 George Washington University evidence review, looking across the available human data, concluded that a human anti-aging benefit is still unproven. The animal case is strong. The human case is early.
For anyone following this space, the honest framing is that rapamycin is one of the most scientifically interesting longevity candidates and one of the least proven in humans at the same time. Both things are true.
What PEARL Did Not Show
Being precise about limitations is part of reading a study well. PEARL did not measure lifespan or mortality, so it cannot tell you whether rapamycin helps people live longer. It ran for 48 weeks, so it says nothing about multi-year or multi-decade effects, safety or otherwise. Its most cited benefit appeared in a subgroup rather than across the whole trial. And with 114 participants, it is a small trial by the standards needed to change clinical practice.
None of that makes the results uninteresting. It means they should be held as hypothesis-generating: a well-run early trial that justifies larger, longer studies rather than a green light. That is the same caution the George Washington University review reached from the wider literature.
What to Track: Biomarkers Worth Monitoring
Whether you are following rapamycin research from the sidelines or discussing options with a prescriber, the value of a clean, longitudinal record is the same. People interested in mTOR biology and metabolic aging, working alongside their providers, commonly keep an eye on a handful of markers over time. Rapamycin can affect glucose and lipid handling in some people, which is why metabolic markers show up repeatedly in the research and in clinical monitoring. The list below is what is commonly discussed, offered so you can organize your own data and bring it to your provider. It is not a recommendation to test, dose, or treat.
Tracking these consistently, as a trend line rather than scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot. A trend tells a story your provider can actually work with. You can browse plain-language explanations of each test in the full [biomarker library](/biomarkers).
[Track your protocol and labs in one place with MyProtocolStack.](/auth/login?mode=signup)
How Rapamycin Compares to Longevity Peptides
Rapamycin is a small-molecule drug, not a peptide, but it lives in the same broader longevity conversation as several research peptides people ask about. It helps to keep the categories straight. Compounds like [MOTS-c](/peptides/mots-c), a mitochondrial-derived peptide studied for metabolic signaling, and [epithalon](/peptides/epithalon), a peptide studied in the context of aging biology, are frequently mentioned in longevity forums. Like rapamycin used for aging, these peptides are investigational for longevity purposes and are not FDA-approved for anti-aging use, and the human evidence for each is limited.
The common thread is that early-stage longevity compounds share a similar evidence profile: intriguing mechanisms, animal or preliminary data, and a shortage of large long-term human trials. If you are comparing options with a provider, our overview of the [best-researched peptides](/best-peptides) lays out what is and is not known for each, so the conversation stays grounded in evidence rather than hype. The tracking discipline is identical across all of them: pick your markers, measure consistently, and let the trend inform the discussion.
The Practical Takeaway for 2026
Here is where the evidence stands. Rapamycin has the strongest animal longevity record of any known compound, PEARL gave us the first placebo-controlled human trial of intermittent low-dose use in healthy older adults, and the standout finding was a lean-mass gain and less reported pain in women on the higher weekly dose, with a safety profile similar to placebo over 48 weeks. At the same time, the trial was small, short, and subgroup-driven, and the wider 2025 review concluded the human anti-aging case is unproven.
For a person tracking their health seriously, the constructive move is not to chase a headline but to keep records clean and provider-ready regardless of which way future trials land. Rapamycin for aging is a prescriber-directed, off-label decision, and this article cannot and does not offer dosing or sourcing guidance. What you can own is the data: consistent, longitudinal, and organized enough to make any conversation with your clinician a better one.
Frequently Asked Questions
Does rapamycin slow aging in humans?
As of 2026, that remains unproven. Rapamycin is the most replicated lifespan-extending compound in animal studies, but human evidence is limited. The PEARL trial, published in the journal Aging in 2025, was the first placebo-controlled randomized trial of intermittent low-dose rapamycin in normal-aging healthy adults, and a 2025 George Washington University evidence review concluded that a human anti-aging benefit is still unproven. Any decision about rapamycin is off-label and belongs with your prescriber.
What did the PEARL trial find?
PEARL randomized 114 adults aged 50 to 85 to weekly 5 mg or 10 mg compounded rapamycin or placebo over 48 weeks. The most notable signal was in women on the 10 mg weekly dose, who gained about 6% lean tissue mass from baseline and reported less pain. Adverse-event rates were similar to placebo across the trial. The trial measured body composition, pain, and safety, and it did not measure lifespan.
Is rapamycin FDA-approved for longevity or anti-aging?
No. Rapamycin, also called sirolimus, is FDA-approved as an immunosuppressant to help prevent organ transplant rejection and for certain other specific uses. It is not FDA-approved for aging, longevity, or healthspan. Using it for those purposes is off-label, meaning a licensed prescriber makes an individualized judgment outside the labeled indication. MyProtocolStack does not provide medical advice or dosing guidance.
How does rapamycin work?
Rapamycin is an mTOR inhibitor. The mTOR pathway is a central nutrient-sensing system that governs when cells grow and divide versus when they conserve and recycle. Slowing mTOR signaling in animals shifts cells toward maintenance and autophagy, and in multiple species this has extended lifespan. Whether that mechanism translates into a meaningful human anti-aging benefit is still unproven.
What biomarkers do people track when discussing rapamycin with a provider?
People following mTOR and metabolic aging commonly keep an eye on metabolic and lipid markers over time, including fasting glucose, HbA1c, triglycerides, LDL cholesterol, and IGF-1, since rapamycin can influence glucose and lipid handling in some people. This is a list of what is commonly discussed, not a recommendation to test or treat. Tracking these consistently gives your provider a trend line to work from, and any interpretation should come from your clinician.
Sources
1. Aging (Aging-US), "Rapamycin in the PEARL trial," 2025. DOI 10.18632/aging.206235. https://www.aging-us.com/article/206235/text
2. PubMed Central, PEARL trial full text, PMC12074816. https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/
3. Aging-US News Room, "Low-Dose Rapamycin Improves Muscle Mass and Well-Being in Aging Adults." https://www.aging-us.com/news-room/low-dose-rapamycin-improves-muscle-mass-and-well-being-in-aging-adults
4. medRxiv preprint, posted August 21, 2024, 2024.08.21.24312372. https://www.medrxiv.org/content/10.1101/2024.08.21.24312372v1
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →